Estrogen induces a rapid increase in microvascular permeability in the rodent uterus, leading to stromal edema and a marked increase in uterine wet weight. This edema is believed to create an environment optimal for the growth and remodeling of the endometrium in preparation for implantation and pregnancy. Increased endometrial microvascular permeability also occurs in conjunction with implantation. Estrogen-induced uterine edema is immediately preceded by an increase in the expression of vascular endothelial growth factor (VEGF), a potent stimulator of microvascular permeability. The objective of this study was to determine to what degree immunoneutralization of VEGF would interfere with a) estradiol-induced uterine edema and b) pregnancy. In the first set of experiments, immature female rats were injected with either VEGF antiserum or normal rabbit serum (NRS) prior to 17␤-estradiol treatment. Rats treated with estradiol alone showed a 57% increase in uterine wet weight at 6 h compared with controls. Injection of 200 or 300 l of VEGF antiserum reduced the response to only 20% and 10% above controls, respectively. In the second set of experiments, young adult female mice were treated with 100 l of either VEGF antiserum or NRS at 1200 h on the fourth day after mating. NRS-treated mice had normal pregnancies. VEGF antiserum, however, completely blocked pregnancy. When VEGF antiserum-treated females were examined on Day 5 for the presence of implantation sites, none were found. These results show that a) VEGF is the major mediator of estrogen-induced increase in uterine vascular permeability and b) VEGF-induced edema is absolutely essential for implantation to take place. estradiol, female reproductive tract, implantation, pregnancy, uterus
INTRODUCTION
One of the earliest events to occur in the rodent uterus after treatment with estrogen is a marked increase in microvascular permeability [1, 2] . This, in combination with an estrogen-induced increase in blood flow [3] , leads to edema in the endometrial stroma [4] . These changes closely resemble those that occur in response to endogenous estrogen during proestrus in the normal adult rodent [5] . Edema is also a characteristic of the human endometrial stroma during both the midproliferative and midsecretory phases of the menstrual cycle [6] [7] [8] , periods that correspond to increases in estrogen production by first the developing follicle and then the corpus luteum. Furthermore, exogenous estrogen induces massive stromal edema in the human endometrium [9] , as it does in the rat and mouse. In the rat and mouse, increases in endometrial microvascular permeability and edema also occur in conjunction with implantation; this presumably involves the brief spike in estrogen that triggers the implantation process [10, 11] . This phenomenon makes it possible to readily visualize implantation sites with the naked eye following i.v. injection of blue dyes, such as Evans Blue, that bind to serum proteins [11] . Marked edema also occurs peripheral to the implanting blastocyst in primates [12] .
The function of increased microvascular permeability and edema in the uterus before and during implantation is not well understood. In general, increased permeability is thought to play essential roles in the induction and direction of tissue growth and remodeling wherever it occurs [13] . Thus, it may first of all be a basic requirement for the rapid growth and differentiation of the endometrium in preparation for implantation and pregnancy. In addition, it appears to play a specific and causal role in the decidualization reaction [11, 14] , which it immediately precedes [15] . In this regard, edema serves to clasp the blastocyst in the uterine lumen [16] , bringing it in intimate association with the epithelium. Edema has also been proposed to cause differential uterine elongation and growth (an increase in uterine length at implantation sites and a decrease between sites), contributing to even spacing between blastocysts [17] . Finally, increased permeability and edema would facilitate the angiogenesis associated with the maternal component of placenta formation [13] . Identification of the mediators of increased permeability in the uterus, therefore, has great significance for understanding the physiological role of uterine vascular permeability and edema in the development of a receptive endometrium and in the implantation process.
The most potent inducer of increased microvascular permeability yet identified is vascular endothelial growth factor/vascular permeability factor (VEGF/VPF, hereafter referred to as VEGF) [18, 19] . Three major forms of VEGF (120, 164, and 188 aa in length in the rat) arise from alternative splicing of a single gene [20] ; all are capable of stimulating microvascular permeability [21] . VEGF is also a specific endothelial cell mitogen that appears to play a central role in angiogenesis [20, 22] . Its angiogenic action may, in part, result from the enhancement of permeability, 1805 VEGF INHIBITION BLOCKS UTERINE EDEMA AND PREGNANCY which invariably precedes new blood vessel growth [13] . We have previously demonstrated that steady-state levels of the mRNA for VEGF increase rapidly in the uterus following estrogen treatment [23] . VEGF and the VEGF receptors Flt-1 and Flk-1 are also expressed in the human endometrium at all stages of the menstrual cycle [24] [25] [26] and levels of VEGF mRNA tend to be higher in the secretory phase [25] , the period of maximum microvascular permeability and greatest edema [6] . It is also likely that VEGF is responsible for the edema associated with implantation based on localization of VEGF, as well as the VEGF receptors, immediately around the implanting blastocyst in several species [27] [28] [29] [30] [31] .
The close temporal and spatial correlation between VEGF expression and increased vascular permeability in the uterus suggests that VEGF is the factor responsible for this phenomenon. Other indirect support for this relationship comes from the similarity in the effects of VEGF on blood vessels observed in other systems [32] and that seen in the uterus in response to estrogen and at implantation sites, namely the formation of intercellular gaps and an increase in the incidence of fenestrae (from 3% to 78%) [33] [34] [35] [36] . Additional indirect support for VEGF's role in these events comes from the observations that prior administration of actinomycin D blocks both estrogen-induced VEGF expression [23] and uterine edema [37] .
It nevertheless remains to be definitively demonstrated that VEGF is the mediator of these events. The i.v. administration of a VEGF monoclonal antibody has been shown to acutely reduce vascular permeability induced by tumor implants in nude mice [38] . In two other studies in mice, polyclonal antisera against hVEGF have been shown to inhibit pathological processes in which VEGF was postulated to play a role: granulomatous inflammation [39] and postoperative adhesion formation [40] . We adopted this approach, therefore, to determine a) whether VEGF is the factor responsible for the increase in microvascular permeability in the uterus after treatment with estrogen and at the time of implantation, and, if so, b) to what degree the latter process is dependent on this increase in permeability.
MATERIALS AND METHODS
Animal studies were conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals and approved by the IACUC of the University of Maryland School of Medicine.
Acute Response to Exogenous Estrogen in Immature Rats
For each experiment, animals were weighed and randomly distributed into treatment groups. Immature, 23-day-old Sprague Dawley rats (Crl: CD[SD] BR strain; Charles River, Wilmington, MA) were anesthetized with ketamine (75 mg/kg)/acepromazine (2.5 mg/kg) to facilitate the tail vein injections. Trial studies demonstrated that anesthesia did not prevent the estrogen-induced increase in uterine wet weight at 6 h (data not shown). A rabbit antiserum made against recombinant human VEGF (provided by Dr. Daniel Connolly, Monsanto, St. Louis, MO; [41] ) or normal rabbit serum (NRS, control) was injected (100-300 l) into a tail vein using a 30-gauge needle. Animals were then injected (i.p.) with 17␤-estradiol (5 g/100 g body weight; Sigma, St. Louis, MO) or vehicle. They were then placed in a warm cage and killed by cervical dislocation 6 h after injection. The reproductive tract was quickly dissected from each animal and placed on moist paper. The uteri were isolated by uniformly cutting at the cervical and tubal junctions and then trimming away the mesometrium. They were then weighed on a Mettler AE50 microbalance. Immediately after weighing, uteri were fixed in 10% buffered formalin. They were then embedded in paraffin, sectioned (8 m), and stained with either hematoxylin-eosin or picric acid-methyl blue. Sections were examined and photographed using an Olympus (Lake Success, NY) BX40 microscope.
Mouse Pregnancy
Experiments on the effects of the VEGF antiserum on implantation were carried out in mice rather than rats. The process of implantation is highly similar in these two species [15, 16] and has been studied most extensively in the former. Eight-to 10-wk-old, virgin female mice (FVB strain; Charles River) were cohoused with adult males and checked daily for the presence of a vaginal plug (Day 1 of pregnancy). At 1200 h on Day 4 of pregnancy, one group of females (controls) received 100 l of NRS (i.v.), while the other group received 100 l of VEGF antiserum. This time was chosen because implantation, as indicted by the blue-dye test, normally begins late on Day 4 in the mouse [15] .
In the first of two experiments, the females (n ϭ 7 control; n ϭ 8 VEGF antiserum-treated) were observed and weighed daily until the normal time of parturition, 19 days (or for at least 1 wk longer if no pups were produced at the expected time). The number of pups born and the length of gestation were recorded. In the second experiment, the blue-dye response on Day 5 of pregnancy was tested. In the latter experiment, all animals were injected (i.v.) with 100 l of 5% Evans Blue Dye in PBS under light anesthesia 24 h following the injection of 100 l of antiserum (n ϭ 3) or NRS (n ϭ 3). Fifteen minutes after the injection of dye, the animals were killed by cervical dislocation. An abdominal incision was made to expose the ovaries and uterus and the reproductive tract was carefully dissected free and photographed. One uterine horn from each animal was processed for histology, serially sectioned (8 m), and stained with picric acid-methyl blue. These sections were examined for the presence of blastocysts and implantation sites.
Statistical Analysis
Uterine weights and litter sizes were compared by analysis of variance followed by appropriate post hoc tests using StatView (Abacus Concepts, Berkeley, CA).
RESULTS
A single injection of estrogen rapidly induces uterine edema in immature rats. The effect of the VEGF antiserum on this response was first examined. In all experiments, immature rats treated with estradiol and NRS showed an average 57% increase in uterine wet weight at 6 h compared with unstimulated controls (Fig. 1) . This increase is similar to that reported in classic studies of estrogen-induced uterine edema by Astwood [4] . Injection of 100 l of VEGF antiserum had no significant effect on the increase in wet weight (Fig. 1, left panel) , although the result was variable from one trial to another, with a 38% reduction in weight occurring in one of the three trials. In the two groups treated with 200 l or 300 l of antiserum, however, the increases in wet weight were only 20% and 9.8% above the control groups, respectively (Fig. 1, center and right panels). These uterine weight values were not statistically different from those in the respective control groups (P Ͼ 0.2 and 0.4, respectively) but were significantly less than the groups treated with estradiol and NRS (P Ͻ 0.01 in both cases).
Cross sections of the uteri from the three treatment groups are shown in Figure 2 . The endometrial stromal cells of control uteri were compact, with closely spaced nuclei and little or no intercellular gaps (Fig. 2, A and B) . As expected, estradiol induced a large decrease in cellular density and a large increase in intercellular space, indicative of fluid accumulation, throughout the endometrial stroma except in the immediate mesometrial area (Fig. 2, C and  D) . In marked contrast with this, uteri from animals treated with VEGF antiserum (200 or 300 l) before estrogen treatment were indistinguishable from control animals (Fig. 2,  E and F) .
The effect of the antiserum to VEGF, given on the fourth day after mating (the normal day of implantation), on pregnancy was then evaluated. All control animals (i.e., NRS treated) in which a vaginal plug had been observed (n ϭ 7) delivered pups. The length of gestation averaged 19 days, and the average litter size (ϮSEM) was 9.3 Ϯ 0.29. In contrast with this and although a vaginal plug had been observed in all animals prior to treatment, 100% of females treated with VEGF antiserum (n ϭ 8) failed to deliver any pups. There was also no significant weight gain in these females following mating (data not shown).
The complete blockade of pregnancy and the lack of any sign of normal weight gain suggested that the VEGF antiserum had probably blocked implantation rather than some later stage of gestation. This was confirmed when the bluedye response was tested. Figure 3 , A-C, shows the bluedye response in control (i.e., pregnant) animals (n ϭ 3). The blue bands, which mark the implantation sites, were distinct, with 10-13 implantation sites per animal. There was also noticeable swelling at each site, giving the uterine horns the normal beads-on-a-string appearance. In the three VEGF antiserum-treated uteri, by contrast, no distinct implantation sites were visible. Some diffuse, light bluish areas could be distinguished in two of these uteri, but they were much less distinct than the well-defined dark blue implantation sites in the control uteri (Fig. 3, D-F) .
Histological analysis was carried out on the same uteri. The implantation sites from control animals had the normal characteristics for Day 5 of pregnancy: hypertrophied decidual cells, elongated blastocysts, clusters of apoptotic nuclei in the antimesometrial primary decidual zone, and a disrupted epithelium (Fig. 4, A and B) . In contrast, there was no sign of implantation in the antiserum-treated animals. Few blastocysts were located, but those that were present were still small and often degenerating. They were usually present at the antimesometrial pole, the correct location for normal initial attachment. The lumen was open, however, and there was no indication of blastocyst invasion, i.e., the uterine epithelium and basement membrane were intact (Fig. 4, C and D) . There was also no sign of stromal decidualization adjacent to these blastocysts.
DISCUSSION
The first significant finding in this study is that VEGF is the principle mediator of the increase in vascular permeability that takes place in the uterus in response to estrogen. The identity of the factor responsible for this event has been sought for more than 50 years. While absolutely essential for this effect, the VEGF-induced increase in permeability would not in itself be sufficient to induce a major increase in uterine edema. That would only occur if there were a simultaneous increase in blood flow as well [42, 43] . It is well established, of course, that estrogen does induce a rapid increase in uterine blood flow [3, 44] . This increase in blood flow may explain why the estrogen plus VEGF antiserum-treated rat uteri tended to be slightly larger than the control uteri (although the difference was not statistically significant) and may also explain the very faint and diffuse blue staining of the uteri of mated, anti-VEGFtreated mice even though no implantation occurred. Increased uterine blood flow would both increase intravascular blood volume (2.5-to 2.7-fold) [45, 46] and raise capillary hydrostatic pressure. The latter would be predicted to increase net filtration without any change in permeability, perhaps resulting in a modest increase in steady-state interstitial fluid volume. The estrogen-induced increase in uterine blood flow is probably mediated primarily by nitric oxide (NO) because it is blocked by inhibitors of NO synthesis [47, 48] . It is not surprising, therefore, that such inhibitors have also been reported to block estrogen-induced uterine edema [49] . It is also possible that factors other than VEGF may be responsible for a small increase in permeability. Some residual permeability-inducing activity, similar to the amount seen here, remained in rat 9L glioma cell-conditioned medium after VEGF was removed by immunoprecipitation [50] .
The response to the three different doses of antibodyno significant effect with 100 l and nearly complete inhibition with 200 or 300 l-suggests that the lower dose was near the threshold necessary to achieve high enough levels within the uterus to block VEGF's effect. This is further suggested by the fact that the lower dose did result in substantial inhibition (38%) in one of three trials.
The second major finding of this study is that VEGF action is necessary for the increase in microvascular permeability that follows the nidatory estrogen signal and that, in the absence of VEGF-induced edema, implantation fails completely. The uteri from VEGF antiserum-treated animals showed no signs of closure of the lumen, breakdown FIG. 2 . Cross-sections of a representative uterine horn from each of the three treatent groups. A, B) Control group; C, D) estradiol plus NRS group; E, F) estradiol plus VEGF antiserum (300 l) group. Original magnifications ϫ100 (A, C, E) and ϫ400 (B, E, F). In each case, the antimesometrial side of the uterus is to the left. of the luminal epithelium, or decidualization. Unable to implant, the blastocysts apparently could not develop further and showed signs of deterioration. Increased permeability is the first definitive event in decidualization and as such has been suggested to be necessary for that complex reaction to take place [11, 14, 51, 52] . The edema associated with implantation is initially generalized, causing closure of the uterine lumen throughout the length of the horn, but then becomes localized at the sight of blastocyst-uterine contact [53, 54] . This suggests that the blastocyst itself may further enhance VEGF production specifically at the implantation site.
The demonstration that an antiserum to VEGF inhibits the rapid increase in uterine edema that follows estrogen treatment strongly suggests that this is the mechanism by which it blocks implantation. Results similar to ours on the effect of an antibody to VEGF on implantation were recently reported in rats [55] . In that study, however, treatment was initiated on Day 3 of pregnancy, well before the nidatory estradiol peak. In that case, it is possible that ovarian steroidogenesis was altered. It has been demonstrated that inhibition of VEGF action can inhibit corpus luteum formation in rats and marmosets [56] [57] [58] . It has also been shown that administration of an anti-VEGF antibody to marmosets during the midluteal phase can significantly lower progesterone production [59] . We cannot, at this time, completely rule out the possibility that inhibition of VEGF action also affected steroid synthesis in our study, but in both the rat and mouse, progesterone levels are already maximal by the morning of Day 4 of pregnancy and the nidatory estradiol rise has already occurred [10, 60, 61] . Coming in the wake of the normal preovulatory rise in estradiol, these events should be sufficient to fully sensitize the uterus for implantation [62] . Furthermore, only brief exposure to low levels of estrogen is needed to trigger implantation [63] . It seems unlikely, therefore, that VEGF antiserum treatment in the middle of Day 4 could shut down progesterone and estradiol synthesis so rapidly and so completely that it would prevent any sign of implantation. Nevertheless, additional studies in which the effects of immunoneutralization of VEGF on implantation in ovariectomized animals given exogenous progesterone and estrogen to induce implantation will be needed to completely rule out this possibility.
There are several possible reasons why edema might be essential for implantation to take place. As discussed previously, one likely role is to occlude the lumen, thereby clasping the blastocysts and bringing them into intimate contact with the epithelial cells lining the uterine lumen. This may trigger the breakdown of the latter, placing the blastocyst into direct contact with the endometrial stroma, where it further enhances local microvascular permeability and the decidualization process. Second, increased microvascular permeability is probably required for the rapid growth and remodeling of the endometrium at implantation sites. Transient edema, induced by ligation of a uterine vein, has in fact been shown to markedly stimulate uterine growth [64] . Edema infuses the extravascular compartment with plasma proteins, such as plasminogen, which participate in the breakdown of the existing extracellular matrix, and fibrinogen, which, after conversion to fibrin, forms a provisional matrix favorable to cell migration, proliferation, and differentiation. Experimental evidence shows that such a sequence does occur in the endometrium in association with estrogen-induced edema. In rats, the well-organized endometrial network of collagen fibers almost completely disappears within 4 h of estrogen treatment, the time when maximum edema is reached [65] . There is also widespread extravascular fibrin deposition in the human endometrium after estrogen treatment [25] . VEGF probably further enhances matrix remodeling by stimulating the production of proteases, such as plasminogen activator and collagenase, by stromal capillary endothelial cells [66, 67] . Increased permeability would also facilitate the extravasation of other blood-borne elements, such as growth factors (e.g., insulinlike growth factors), platelets, and leukocytes, further optimizing conditions for endometrial remodeling. Furthermore, it may also enhance the efficiency of delivery of oxygen and basic nutrients to areas of heightened cell activity by creating a more direct circulatory pathway-from capillaries through the interstitial spaces to the lumenthereby greatly reducing normal diffusional distances. Finally, the increase in permeability may serve as a positive feedback mechanism in estrogen action. When levels of estrogen are low, uterine capillaries are relatively impermeable to estradiol, which circulates bound to serum proteins [68] . By facilitating the passage of these proteins to the interstitium, increased permeability would enhance estrogen delivery as well.
In summary, these studies support the propositions that a) VEGF is the major mediator of the estrogen-induced increase in uterine vascular permeability and edema and b) VEGF-induced edema is absolutely essential for implantation to take place. This opens new avenues of investigation to better define the physiological functions of both VEGF and the edema it induces in the establishment of pregnancy.
